Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial

被引：0
|
作者：
Samson, Benoit
Tournigand, Christophe
Scheithauer, Werner
Lledo, Gerard
Viret, Frederic
Andre, Thierry
Ramee, Jean Francois
Tubiana-Mathieu, Nicole
Dauba, Jerome
Dupuis, Olivier
Rinaldi, Yves
Mabro, May
Aucoin, Nathalie
Khalil, Ahmed
Latreille, Jean
Louvet, Christophe
Brusquant, David
Bonnetain, Franck
Chibaudel, Benoist
De Gramont, Aimery
机构：
[1] Hop Charles LeMoyne, Quebec City, PQ, Canada
[2] Hop Henri Mondor, F-94010 Creteil, France
[3] Med Univ Vienna, Vienna, Austria
[4] Hop Prive Jean Mermoz, Lyon, France
[5] Inst J Paoli I Calmettes, F-13009 Marseille, France
[6] Hop St Antoine, F-75571 Paris, France
[7] Ctr Catherine Sienne, Nantes, France
[8] CHU Limoges, Limoges, France
[9] Ctr Hosp Layne, Mt De Marsan, France
[10] Clin Victor Hugo, Le Mans, France
[11] Hop Ambroise Pare, Marseille, France
[12] Hop Foch, Suresnes, France
[13] Cite Sante Laval, Laval, PQ, Canada
[14] Hop Tenon, F-75970 Paris, France
[15] Hop Charles LeMoyne, Greenfield Pk, PQ, Canada
[16] Inst Mutualiste Montsouris, Dept Oncol, Paris, France
[17] GERCOR, Paris, France
[18] CHU Besancon, F-25030 Besancon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.448
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
448
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CLINICAL OUTCOMES OF BEVACIZUMAB USED IN COMMUNITY ONCOLOGY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS WITH CONFIRMED KRAS-STATUS
    Cartwright, Thomas
    Yim, Yeun Mi
    Yu, Elaine
    Rahul, Dhanda
    Tseng, Wan-Yu
    Forsyth, Michael
    Lopez, William
    ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99
  • [42] Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX)
    Cunningham, David
    Lang, Istvan
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dongbok
    Jonker, Derek J.
    Osborne, Stuart
    Andre, Niko Alexander
    Waterkamp, Daniel
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [43] FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) who have failed first-line bev plus oxaliplatin-based therapy: The randomized phase III EAGLE study.
    Tamagawa, Hiroshi
    Iwamoto, Shigeyoshi
    Takahashi, Takao
    Nakamura, Masato
    Munemoto, Yoshinori
    Kato, Takeshi
    Hata, Taishi
    Denda, Tadamichi
    Morita, Yoshitaka
    Inukai, Michio
    Kunieda, Katsuyuki
    Nagata, Naoki
    Kurachi, Kiyotaka
    Ina, Kenji
    Oshiro, Takashi
    Shimoyama, Tatsu
    Baba, Hideo
    Oba, Koji
    Sakamoto, Junichi
    Mishima, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Evaluation of prognostic markers in patients (pts) with metastatic colorectal cancer (mCRC) treated with a bevacizumab (bev) based chemotherapy (ctx) at the West German Cancer Center
    Lueckerath, M.
    Kasper, S.
    Paul, A.
    Gerken, G.
    Schmid, K. W.
    Meiler, J.
    Wiesweg, M.
    Neuhaus, I.
    Dechene, A.
    Mende, B.
    Schumacher, B.
    Markus, P.
    Schuler, M.
    Virchow, I.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 77 - 77
  • [45] The Role of Bevacizumab (B) in the Maintenance Treatment After Chemotherapy (CT) for Metastatic Colorectal Cancer (mCRC) Patients (pts) - an Italian Multicenter Retrospective Analysis
    Moscetti, L.
    Fabbri, A.
    Pochesci, A.
    Alesini, D.
    Gemma, D.
    Grande, R.
    Pavese, I.
    Sperduti, I.
    Franco, D.
    Ruggeri, E. M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S429 - S429
  • [46] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Steffens, Claus-Christoph
    Brugger, Wolfram
    Hapke, Gunnar
    Illerhaus, Gerald
    Bluemner, Ernst
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [47] Efficacy and safety of bevacizumab (BEV) plus chemotherapy in Chinese patients (pts) with metastatic colorectal cancer (mCRC): Results from the ARTIST study.
    Guan, Z.
    Xu, J.
    Luo, R.
    Feng, F.
    Wang, L.
    Shen, L.
    Yu, S.
    Ba, Y.
    Liang, J.
    Wang, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] CHRONOCHEMOTHERAPY (CCT) WITH FLUOROURACIL, OXALIPLATIN, IRINOTECAN,, FOLINIC ACID (FOLFOXIRI)± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC): A PHASE 2 TRIAL
    Tumolo, Salvatore
    Boccalon, Massimo
    Marzano, Bernardo
    Fanti, Gianni
    Scata, Armando
    Santeufemia, Davide Adriano
    Del Conte, Alessandro
    Chiara, Giordano
    Tosolini, Giancarlo
    Marus, Walli
    Sulfaro, Sandro
    ANNALS OF ONCOLOGY, 2009, 20
  • [49] CHRONOCHEMOTHERAPY (CCT) WITH FLUOROURACIL, OXALIPLATIN, FOLINIC ACID, IRINOTECAN (FOLFOXIRI) +/-BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC): A PHASE 2 TRIAL
    Lo Re, G.
    Tumolo, S.
    Marzano, B.
    Fanti, G.
    Scata, A.
    Chiara, G.
    Tosolini, G.
    Marus, W.
    Sulfaro, S.
    Santeufemia, D.
    Donadon, V
    Casarin, P.
    Balbi, M.
    Spaziante, R.
    Mancinelli, P.
    ANNALS OF ONCOLOGY, 2009, 20 : 33 - 33
  • [50] A phase II trial of alternating mXELOX/mXELIRI plus bevacizumab (BEV) as first-line treatment for metastatic colorectal cancer (mCRC)
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Xu, Hanfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345